WHO Sounds Warning Over Critical Scarcity of Weight-Loss Injections
Under one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy can access them, states the WHO as it releases its initial advice on the therapies.
With more than one billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be managed with holistic and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key barriers to universal access to the treatments that can assist patients in reducing significant weight, says the body.
GLP-1 Therapy Supply Crisis
Even in the present best projected case, the supply of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The recommendation urges nations and manufacturers to increase availability, via approaches like voluntary licensing.
A patent on a key compound – the primary component of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Jabs Work
These medications mimick a biological compound to slow digestion, reduce hunger and increase the sense of being full so users reduce food intake.
People typically start to lose weight within a few weeks of beginning the regular doses.
Evidence points to patients may regain a significant portion a year later of halting the treatment, because their typical appetite come back.
Being carrying excess weight elevates your chance for contracting medical conditions, including diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity impacts people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
